Circulating Insulin-like peptide 5 concentrations may reflect colonic exposure to bile acids and help stratify treatment response in patients with chronic diarrhea.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
Home use of ondansetron following emergency care for pediatric gastroenteritis lowers the risk of moderate-to-severe illness within 7 days, without increasing serious adverse events.